Almirall partners with CrystalO to develop ion channel small-molecule dermatology drugs

• Almirall entered a collaboration and licensing deal with CrystalO to discover and develop new small-molecule dermatology drugs targeting ion channels.
• CrystalO will run discovery, optimization, IND-enabling work, early clinical development through proof-of-concept studies.
• Almirall will lead global development, manufacturing, commercialization outside mainland China; CrystalO keeps mainland China rights.
• CrystalO will receive an upfront payment, milestone payments across R&D, regulatory, commercialization stages, tiered royalties on net sales.
• CrystalO will pay Almirall tiered royalties on mainland China sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Almirall SA published the original content used to generate this news brief via Business Wire (Ref. ID: 202608100200BIZWIRE_USPR_____20260809_BW965150) on August 10, 2026, and is solely responsible for the information contained therein.